Literature DB >> 35579799

MAFLD Predicts the Risk of Cardiovascular Disease Better than NAFLD in Asymptomatic Subjects with Health Check-Ups.

Hyoeun Kim1, Chan Joo Lee2, Byoung Kwon Lee3, Seung Up Kim4,5, Jung Il Lee6,7, Sang Hoon Ahn6,8, Kwan Sik Lee6,7, Su Jung Baik9.   

Abstract

BACKGROUND AND AIM: Metabolic dysfunction-associated fatty liver disease (MAFLD) was proposed to compensate for the conventional concept of nonalcoholic fatty liver disease (NAFLD). We investigated the superiority of MAFLD versus NAFLD in predicting the risk of atherosclerotic cardiovascular disease (ASCVD).
METHODS: A total of 2,144 subjects without a history of ASCVD, who underwent a comprehensive medical health check-up, were selected for the study. The associations between fatty liver status and coronary risk surrogates, such as coronary artery calcium score (CACS), coronary artery disease, quantitative stenosis grade, and 10-year ASCVD risk, were analyzed.
RESULTS: MAFLD and NAFLD were identified in 995 (46.4%) and 891 (41.6%) subjects, respectively. Subjects with MAFLD or NAFLD were more likely to be male and had a significantly higher prevalence of central obesity, obesity, hypertension, diabetes, and dyslipidemia (all, p < 0.05) than their counterparts. In terms of coronary risk surrogates, the MAFLD or NAFLD population had a significantly higher proportion of subjects with CACS > 100, coronary artery disease, higher grade of coronary artery stenosis, and higher 10-year ASCVD risk (all, p < 0.05) than their counterparts. Multivariable logistic regression models showed an independent association between MAFLD/NAFLD and coronary risk surrogates (all, p < 0.05). However, NAFLD only, defined as 'NAFLD, but not MAFLD,' was not associated with an increased coronary risk, compared to MAFLD.
CONCLUSIONS: Although both MAFLD and NAFLD discriminated different ASCVD risks, MAFLD predicted the risk of ASCVD better than NAFLD in asymptomatic subjects who underwent medical health check-ups.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Cardiovascular disease, risk assessment; Metabolic dysfunction-associated fatty liver disease; Nonalcoholic fatty liver disease

Mesh:

Substances:

Year:  2022        PMID: 35579799     DOI: 10.1007/s10620-022-07508-6

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.487


  44 in total

Review 1.  The Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 2: Management and special groups.

Authors:  Shiv Chitturi; Vincent Wai-Sun Wong; Wah-Kheong Chan; Grace Lai-Hung Wong; Simon Kin-Hung Wong; Jose Sollano; Yen-Hsuan Ni; Chun-Jen Liu; Yu-Cheng Lin; Laurentius Adrianto Lesmana; Seung Up Kim; Etsuko Hashimoto; Masahide Hamaguchi; Khean-Lee Goh; Jiangao Fan; Ajay Duseja; Yock Young Dan; Yogesh Chawla; Geoff Farrell; Henry Lik-Yuen Chan
Journal:  J Gastroenterol Hepatol       Date:  2018-01       Impact factor: 4.029

Review 2.  Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 1: Definition, risk factors and assessment.

Authors:  Vincent Wai-Sun Wong; Wah-Kheong Chan; Shiv Chitturi; Yogesh Chawla; Yock Young Dan; Ajay Duseja; Jiangao Fan; Khean-Lee Goh; Masahide Hamaguchi; Etsuko Hashimoto; Seung Up Kim; Laurentius Adrianto Lesmana; Yu-Cheng Lin; Chun-Jen Liu; Yen-Hsuan Ni; Jose Sollano; Simon Kin-Hung Wong; Grace Lai-Hung Wong; Henry Lik-Yuen Chan; Geoff Farrell
Journal:  J Gastroenterol Hepatol       Date:  2018-01       Impact factor: 4.029

Review 3.  Redefining fatty liver disease: an international patient perspective.

Authors:  Gamal Shiha; Marko Korenjak; Wayne Eskridge; Teresa Casanovas; Patricia Velez-Moller; Sari Högström; Ben Richardson; Christopher Munoz; Sólveig Sigurðardóttir; Alioune Coulibaly; Miskovikj Milan; Fabiana Bautista; Nancy Wai Yee Leung; Vicki Mooney; Solomon Obekpa; Eva Bech; Naveen Polavarapu; Abd Elkhalek Hamed; Temur Radiani; Edhie Purwanto; Bisi Bright; Mohammad Ali; Cecil Kwaku Dovia; Lone McColaugh; Yiannoula Koulla; Jean-François Dufour; Reham Soliman; Mohammed Eslam
Journal:  Lancet Gastroenterol Hepatol       Date:  2020-10-05

4.  Prevalence of non-alcoholic fatty liver disease and its association with cardiovascular disease in patients with type 1 diabetes.

Authors:  Giovanni Targher; Lorenzo Bertolini; Roberto Padovani; Stefano Rodella; Giacomo Zoppini; Isabella Pichiri; Claudia Sorgato; Luciano Zenari; Enzo Bonora
Journal:  J Hepatol       Date:  2010-06-20       Impact factor: 25.083

5.  Metabolic and adipokine profile of Chinese patients with nonalcoholic fatty liver disease.

Authors:  Vincent Wai-Sun Wong; Alex Yui Hui; Steven Woon-Choy Tsang; Joyce Lai-Yee Chan; Ada Mei-Ling Tse; Kui-Fat Chan; Wing-Yee So; Angela Yuen-Shan Cheng; Wing-Fung Ng; Grace Lai-Hung Wong; Joseph Jao-Yiu Sung; Henry Lik-Yuen Chan
Journal:  Clin Gastroenterol Hepatol       Date:  2006-08-14       Impact factor: 11.382

6.  Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease.

Authors:  Nicola Villanova; Simona Moscatiello; Stefano Ramilli; Elisabetta Bugianesi; Donatella Magalotti; Ester Vanni; Marco Zoli; Giulio Marchesini
Journal:  Hepatology       Date:  2005-08       Impact factor: 17.425

Review 7.  New trends on obesity and NAFLD in Asia.

Authors:  Jian-Gao Fan; Seung-Up Kim; Vincent Wai-Sun Wong
Journal:  J Hepatol       Date:  2017-06-19       Impact factor: 25.083

8.  Nonalcoholic Fatty Liver Disease and Sarcopenia Are Independently Associated With Cardiovascular Risk.

Authors:  Eugene Han; Yong-Ho Lee; Young Dae Kim; Beom Kyung Kim; Jun Yong Park; Do Young Kim; Sang Hoon Ahn; Byung-Wan Lee; Eun Seok Kang; Bong-Soo Cha; Kwang-Hyub Han; Hyo Suk Nam; Ji Hoe Heo; Seung Up Kim
Journal:  Am J Gastroenterol       Date:  2020-04       Impact factor: 10.864

9.  Liver Phenotypes of European Adults Heterozygous or Homozygous for Pi∗Z Variant of AAT (Pi∗MZ vs Pi∗ZZ genotype) and Noncarriers.

Authors:  Carolin V Schneider; Karim Hamesch; Annika Gross; Mattias Mandorfer; Linda S Moeller; Vitor Pereira; Monica Pons; Pawel Kuca; Matthias C Reichert; Federica Benini; Barbara Burbaum; Jessica Voss; Marla Gutberlet; Vivien Woditsch; Cecilia Lindhauer; Malin Fromme; Julia Kümpers; Lisa Bewersdorf; Benedikt Schaefer; Mohammed Eslam; Robert Bals; Sabina Janciauskiene; Joana Carvão; Daniel Neureiter; Biaohuan Zhou; Katharina Wöran; Heike Bantel; Andreas Geier; Timm Dirrichs; Felix Stickel; Alexander Teumer; Jef Verbeek; Frederik Nevens; Olivier Govaere; Marcin Krawczyk; Tania Roskams; Johannes Haybaeck; Georg Lurje; Joanna Chorostowska-Wynimko; Joan Genesca; Thomas Reiberger; Frank Lammert; Aleksander Krag; Jacob George; Quentin M Anstee; Michael Trauner; Christian Datz; Nadine T Gaisa; Helmut Denk; Christian Trautwein; Elmar Aigner; Pavel Strnad
Journal:  Gastroenterology       Date:  2020-05-04       Impact factor: 22.682

Review 10.  MAFLD enhances clinical practice for liver disease in the Asia-Pacific region.

Authors:  Takumi Kawaguchi; Tsubasa Tsutsumi; Dan Nakano; Mohammed Eslam; Jacob George; Takuji Torimura
Journal:  Clin Mol Hepatol       Date:  2021-11-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.